Resistance to EGFR-Targeted Therapy: A Family Affair

Gregory Vlacich; Robert J. Coffey

doi:10.1016/j.ccr.2011.10.006

Resistance to EGFR-Targeted Therapy: A Family Affair

Gregory Vlacich
, Robert J. Coffey

Research output: Contribution to journal › Short survey › peer-review

54 Scopus citations

Abstract

The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.

Original language	English
Pages (from-to)	423-425
Number of pages	3
Journal	Cancer Cell
Volume	20
Issue number	4
DOIs	https://doi.org/10.1016/j.ccr.2011.10.006
State	Published - Oct 18 2011

Access to Document

10.1016/j.ccr.2011.10.006

Cite this

@article{5935c90d269f4fa4ae7074d3e5c87b63,

title = "Resistance to EGFR-Targeted Therapy: A Family Affair",

abstract = "The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.",

author = "Gregory Vlacich and Coffey, \{Robert J.\}",

year = "2011",

month = oct,

day = "18",

doi = "10.1016/j.ccr.2011.10.006",

language = "English",

volume = "20",

pages = "423--425",

journal = "Cancer Cell",

issn = "1535-6108",

number = "4",

}

TY - JOUR

T1 - Resistance to EGFR-Targeted Therapy

T2 - A Family Affair

AU - Vlacich, Gregory

AU - Coffey, Robert J.

PY - 2011/10/18

Y1 - 2011/10/18

N2 - The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.

AB - The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.

UR - https://www.scopus.com/pages/publications/80054747872

U2 - 10.1016/j.ccr.2011.10.006

DO - 10.1016/j.ccr.2011.10.006

M3 - Short survey

C2 - 22014569

AN - SCOPUS:80054747872

SN - 1535-6108

VL - 20

SP - 423

EP - 425

JO - Cancer Cell

JF - Cancer Cell

IS - 4

ER -

Resistance to EGFR-Targeted Therapy: A Family Affair

Abstract

Access to Document

Other files and links

Fingerprint

Cite this